Security key
98937L105
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 36,047
- Total 13F value
- $969,691
- Share change
- -25,123
- SEC-reported price per share
- $26.97
- Number of holders
- 16
- Value change
- -$648,549
- Number of buys
- 10
- Number of sells
- 3
- Shares outstanding
- 65,740,420
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2026
Institutions
16
Top holders
10
ZBIO full security history
Ownership snapshot
Full 13F holder table
Zenas BioPharma, Inc. SEC filings
Zenas BioPharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98937L105
Recent filing periods:
Ownership snapshot
Top reported holders of ZBIO - Zenas BioPharma, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
9/15
Latest evidence
30 Sep 2026
13D/G
13F
3/4/5
Lead comparable stake: 14%
6 rows are not safely comparable across share classes.
13D/G row: FMR LLC
Showing 1-6 of 15 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 14%.
9 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
14%
InnoCare Pharma Inc.
10%
WELLINGTON MANAGEMENT GROUP LLP
10%
SR ONE CAPITAL MANAGEMENT, LLC
7.7%
Moulder Leon O Jr.
5.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13D/G
13F
Company
|
14%
Reported 13D/G
· 31 Dec 2025
|
$277,876,336
7,652,255 shares
|
+$109,228,632 | 31 Dec 2025 |
| InnoCare Pharma Inc. |
13D/G
3/4/5
10%+ Owner
|
10%
Reported 13D/G
· 26 Aug 2026
|
$217,630,000
7,000,000 shares
|
+$62,180,000 | 26 Aug 2026 |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
13F
Company
|
10%
Reported 13D/G
· 31 Aug 2026
|
$204,141,106
6,566,134 shares
|
$0 | 31 Aug 2026 |
| SR ONE CAPITAL MANAGEMENT, LLC |
13D/G
3/4/5
10%+ Owner
|
7.7%
Reported 13D/G
· 13 Aug 2026
|
$148,264,043
5,037,854 shares
|
$0 | 13 Aug 2026 |
| Moulder Leon O Jr. |
13D/G
3/4/5
Chief Executive Officer, Director
|
5.1%
Reported 13D/G
· 29 Apr 2026
|
$67,767,315
3,220,880 shares
|
+$4,017,777 | 29 Apr 2026 |
| BlackRock, Inc. |
13D/G
13F
Company
|
5%
Reported 13D/G
· 30 Sep 2026
|
$88,651,285
3,287,021 shares
|
$0 | 30 Sep 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
16
Shares
36,047
Rows available
16
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2026 vs Q2 2026 Across Filers
Q2 2026 holders
143
Q3 2026 holders
16
Holder diff
-127
| Investor | Q2 2026 Shares | Q3 2026 Shares | Share Diff | Share Chg % | Q2 2026 value | Q3 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend